Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.

[No authors listed]

Cardiovasc J Afr. 2008 May-Jun;19(3):159-62. No abstract available.

2.

PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes.

Marx N.

Diab Vasc Dis Res. 2008 Nov;5(4):345-6. doi: 10.3132/dvdr.2008.048. No abstract available.

PMID:
18958845
3.

Pioglitazone vs glimepiride in the PERISCOPE trial.

Shah R.

JAMA. 2008 Aug 20;300(7):787-8; author reply 788. doi: 10.1001/jama.300.7.787-b. No abstract available.

PMID:
18714054
4.

Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.

Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Ikeda H, Yamagishi S, Imaizumi T.

JACC Cardiovasc Imaging. 2013 Nov;6(11):1172-82. doi: 10.1016/j.jcmg.2013.09.004.

5.

Pioglitazone vs glimepiride in the PERISCOPE trial.

Fresco C.

JAMA. 2008 Aug 20;300(7):787; author reply 788. doi: 10.1001/jama.300.7.787-a. No abstract available.

PMID:
18714055
6.

Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.

Davidson MH, Beam CA, Haffner S, Perez A, D'Agostino R Sr, Mazzone T.

Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1873-6. doi: 10.1161/ATVBAHA.110.207696. Epub 2010 Jun 24.

7.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators.

JAMA. 2008 Apr 2;299(13):1561-73. doi: 10.1001/jama.299.13.1561. Epub 2008 Mar 31.

PMID:
18378631
8.

Pioglitazone vs glimepiride and carotid intima-media thickness.

Giugliano D, Esposito K.

JAMA. 2007 Mar 28;297(12):1315-6; author reply 1316-7. No abstract available.

PMID:
17392236
10.

Seeking alternatives to Hard End Points: is imaging the best APPROACH?

Finn AV, Chandrashekhar Y, Narula J.

Circulation. 2010 Mar 16;121(10):1165-8. doi: 10.1161/CIR.0b013e3181d83b4f. Epub 2010 Mar 1. No abstract available.

11.
12.

[Tough glucose reduction necessary in newly diagnosed diabetes].

Rydén M.

Lakartidningen. 2010 Nov 10-16;107(45):2810-4. Review. Swedish. No abstract available.

PMID:
21179867
13.

Pioglitazone vs glimepiride and carotid intima-media thickness.

Kida Y, Sato T.

JAMA. 2007 Mar 28;297(12):1316; author reply 1316-7. No abstract available.

PMID:
17392237
14.

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM.

JAMA. 2006 Dec 6;296(21):2572-81. Epub 2006 Nov 13.

PMID:
17101640
15.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

Diabetes Care. 2004 Jan;27(1):141-7.

PMID:
14693980
16.

Does PERISCOPE provide a new perspective on diabetic treatment?

Steg PG, Marre M.

JAMA. 2008 Apr 2;299(13):1603-4. doi: 10.1001/jama.299.13.1603. Epub 2008 Mar 31. No abstract available.

PMID:
18378632
17.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
18.

Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.

Kataoka Y, Shao M, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, Nicholls SJ.

Eur J Prev Cardiol. 2013 Apr;20(2):209-17. doi: 10.1177/2047487312437931. Epub 2012 Jan 31.

PMID:
22345692
19.

Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.

Roden M, Mariz S, Brazzale AR, Pacini G.

J Intern Med. 2009 Apr;265(4):476-87. doi: 10.1111/j.1365-2796.2008.02040.x.

20.

[Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].

Ohmura E, Hosaka D, Imai Y, Kawazu S.

Nihon Rinsho. 2002 Sep;60 Suppl 9:470-5. Review. Japanese. No abstract available.

PMID:
12387036

Supplemental Content

Support Center